OTC Markets OTCPK - Delayed Quote USD

Evofem Biosciences, Inc. (EVFM)

0.0080
-0.0004
(-4.76%)
At close: May 13 at 4:00:00 PM EDT
Loading Chart for EVFM
  • Previous Close 0.0084
  • Open 0.0084
  • Bid 0.0084 x --
  • Ask 0.0087 x --
  • Day's Range 0.0084 - 0.0084
  • 52 Week Range 0.0060 - 0.0200
  • Volume 45,399
  • Avg. Volume 495,408
  • Market Cap (intraday) 906,848
  • Beta (5Y Monthly) -1.00
  • PE Ratio (TTM) --
  • EPS (TTM) -0.1200
  • Earnings Date Aug 12, 2025 - Aug 18, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. The company's commercial products include PHEXXI, a vaginal gel for the prevention of pregnancy; and SOLOSEC, a single-dose oral antimicrobial agent for the treatment of bacterial vaginosis and trichomoniasis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

www.evofem.com

32

Full Time Employees

December 31

Fiscal Year Ends

Recent News: EVFM

View More

Performance Overview: EVFM

Trailing total returns as of 5/13/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

EVFM
20.00%
S&P 500 (^GSPC)
0.08%

1-Year Return

EVFM
38.46%
S&P 500 (^GSPC)
12.74%

3-Year Return

EVFM
99.99%
S&P 500 (^GSPC)
46.29%

5-Year Return

EVFM
100.00%
S&P 500 (^GSPC)
108.74%

Compare To: EVFM

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: EVFM

View More

Valuation Measures

Annual
As of 5/13/2025
  • Market Cap

    952.19k

  • Enterprise Value

    46.92M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.03

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    2.42

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -45.76%

  • Return on Assets (ttm)

    -27.94%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    19.36M

  • Net Income Avi to Common (ttm)

    -8.96M

  • Diluted EPS (ttm)

    -0.1200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    127k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -3.88M

Research Analysis: EVFM

View More

Company Insights: EVFM

Research Reports: EVFM

View More

People Also Watch